A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia

Stephen Lam, Sumithra J Mandrekar, Yaron Gesthalter, Katie L. Allen Ziegler, Drew K. Seisler, David Eric Midthun, Jenny T. Mao, Marie Christine Aubry, Annette McWilliams, Don D. Sin, Tawimas Shaipanich, Gang Liu, Evan Johnson, Andrea Bild, Marc E. Lenburg, Diana N. Ionescu, John Mayo, Joanne Yi, Henry Tazelaar, William S. HarmsenJudith Smith, Avrum E. Spira, Jennifer Beane, Paul John Limburg, Eva Szabo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myoinositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent.

Original languageEnglish (US)
Pages (from-to)906-914
Number of pages9
JournalCancer Prevention Research
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Inositol
Placebos
Bronchoalveolar Lavage Fluid
Bronchoscopy
Phosphatidylinositol 3-Kinases
Transcriptome
Clinical Trials, Phase I
Oxidants
Interleukin-6
Lung Neoplasms
Epithelium
Antioxidants
Biomarkers
Clinical Trials
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia. / Lam, Stephen; Mandrekar, Sumithra J; Gesthalter, Yaron; Allen Ziegler, Katie L.; Seisler, Drew K.; Midthun, David Eric; Mao, Jenny T.; Aubry, Marie Christine; McWilliams, Annette; Sin, Don D.; Shaipanich, Tawimas; Liu, Gang; Johnson, Evan; Bild, Andrea; Lenburg, Marc E.; Ionescu, Diana N.; Mayo, John; Yi, Joanne; Tazelaar, Henry; Harmsen, William S.; Smith, Judith; Spira, Avrum E.; Beane, Jennifer; Limburg, Paul John; Szabo, Eva.

In: Cancer Prevention Research, Vol. 9, No. 12, 01.12.2016, p. 906-914.

Research output: Contribution to journalArticle

Lam, S, Mandrekar, SJ, Gesthalter, Y, Allen Ziegler, KL, Seisler, DK, Midthun, DE, Mao, JT, Aubry, MC, McWilliams, A, Sin, DD, Shaipanich, T, Liu, G, Johnson, E, Bild, A, Lenburg, ME, Ionescu, DN, Mayo, J, Yi, J, Tazelaar, H, Harmsen, WS, Smith, J, Spira, AE, Beane, J, Limburg, PJ & Szabo, E 2016, 'A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia', Cancer Prevention Research, vol. 9, no. 12, pp. 906-914. https://doi.org/10.1158/1940-6207.CAPR-15-0254
Lam, Stephen ; Mandrekar, Sumithra J ; Gesthalter, Yaron ; Allen Ziegler, Katie L. ; Seisler, Drew K. ; Midthun, David Eric ; Mao, Jenny T. ; Aubry, Marie Christine ; McWilliams, Annette ; Sin, Don D. ; Shaipanich, Tawimas ; Liu, Gang ; Johnson, Evan ; Bild, Andrea ; Lenburg, Marc E. ; Ionescu, Diana N. ; Mayo, John ; Yi, Joanne ; Tazelaar, Henry ; Harmsen, William S. ; Smith, Judith ; Spira, Avrum E. ; Beane, Jennifer ; Limburg, Paul John ; Szabo, Eva. / A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 12. pp. 906-914.
@article{d5186fbe6d03494ebd17a8e829d7ffb3,
title = "A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia",
abstract = "Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3{\%} versus 13.9{\%} and 47.4{\%} versus 33.3{\%}, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myoinositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent.",
author = "Stephen Lam and Mandrekar, {Sumithra J} and Yaron Gesthalter and {Allen Ziegler}, {Katie L.} and Seisler, {Drew K.} and Midthun, {David Eric} and Mao, {Jenny T.} and Aubry, {Marie Christine} and Annette McWilliams and Sin, {Don D.} and Tawimas Shaipanich and Gang Liu and Evan Johnson and Andrea Bild and Lenburg, {Marc E.} and Ionescu, {Diana N.} and John Mayo and Joanne Yi and Henry Tazelaar and Harmsen, {William S.} and Judith Smith and Spira, {Avrum E.} and Jennifer Beane and Limburg, {Paul John} and Eva Szabo",
year = "2016",
month = "12",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0254",
language = "English (US)",
volume = "9",
pages = "906--914",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia

AU - Lam, Stephen

AU - Mandrekar, Sumithra J

AU - Gesthalter, Yaron

AU - Allen Ziegler, Katie L.

AU - Seisler, Drew K.

AU - Midthun, David Eric

AU - Mao, Jenny T.

AU - Aubry, Marie Christine

AU - McWilliams, Annette

AU - Sin, Don D.

AU - Shaipanich, Tawimas

AU - Liu, Gang

AU - Johnson, Evan

AU - Bild, Andrea

AU - Lenburg, Marc E.

AU - Ionescu, Diana N.

AU - Mayo, John

AU - Yi, Joanne

AU - Tazelaar, Henry

AU - Harmsen, William S.

AU - Smith, Judith

AU - Spira, Avrum E.

AU - Beane, Jennifer

AU - Limburg, Paul John

AU - Szabo, Eva

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myoinositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent.

AB - Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myoinositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent.

UR - http://www.scopus.com/inward/record.url?scp=85008423171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008423171&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0254

DO - 10.1158/1940-6207.CAPR-15-0254

M3 - Article

C2 - 27658890

AN - SCOPUS:85008423171

VL - 9

SP - 906

EP - 914

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 12

ER -